Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...

Our analysis is essentially based on how ... between trends in earnings estimate revisions and short-term stock price movements. Pfizer is expected to post earnings of $0.67 per share for the ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer (PFE) shares slipped on Wednesday after The Wall Street Journal reported that U.S. authorities are investigating ...

Our analysis is essentially based on ... in earnings estimate revisions and short-term stock price movements. For the current quarter, Pfizer is expected to post earnings of $0.67 per share ...

Secondly, I will conduct a comparative analysis of those Johnson ... in the next five years relative to Pfizer. In my opinion, Johnson & Johnson stock shows a number of signs of being overbought ...